drugset / Trial / NCT04353193
Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial.
RandomizedParallel-groupSingle-blindTreatment
Summary
Clinical trial to compare the effects of terlipressin and octreotide in the reduction of portal hypertension measured as hepatic venous pressure gradient (HVPG) in patients with liver cirrhosis
Timeline
- Start
- 2020-06
- Primary completion
- 2022-02
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octreotide | Peptide | 50 ug | Intravenous |
| Subject | Terlipressin | Peptide | 1 mg | Intravenous |
| Subject | Terlipressin | Peptide | 2 mg | Intravenous |